New drug combo aims to unleash immune system on kaposi sarcoma tumors

NCT ID NCT04303117

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated Apr 24, 2026 · Updated 4 times

Summary

This study tests two non-chemotherapy drugs, PDS01ADC and M7824, in people with advanced Kaposi sarcoma (KS) that has not responded well to prior treatment. PDS01ADC helps the immune system attack tumors, while M7824 blocks cancer cells' ability to hide. The goal is to see if these drugs can shrink KS tumors and improve quality of life. About 80 adults with KS will receive the drugs for up to 96 weeks, with regular monitoring for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

KAPOSI SARCOMA